Compare AbbVie Inc (ABBV) vs Alibaba Group (BABA) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Alibaba (BABA) trades at $128.41, up 1.26% today, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with solid fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 19.7 appear reasonable. The company announced a $1.05 dividend for H1-26 and faces multiple class-action lawsuits filed in August 2026, alleging securities fraud between June 2025 and June 2026.

Outlook is mixed: bullish analyst consensus (86% buy ratings) and a $195 price target suggest upside, but legal risks and earnings volatility pose headwinds. Investment opportunity hinges on AI growth and cloud strength, while risks include litigation outcomes and competitive pressures in China.